Bispecific anti-MUC16/CD3 moAb inhibited the growth of murine peritoneal tumorsConjugate of anti-MUC16 moAb with cytotoxic maytansinoid tubulin inhibitor DM4. In recurrent ovarian cancer, this combination showed 28% response rate, mostly in the form of partial response. Here, MUC16 is linked to ovarian cancer.